Prof. Dr. A (Ton) Hagenbeek (1948 – 2021)

Professor of Hematology, Academic Medical Center (AMC) , Dept. of Hematology , University of Amsterdam.

Today, the international community has lost a true leader in the field of hematology. Prof. Hagenbeek has touched and inspired many doctors and scientists in carrying out the best cancer care and research for patients. His boundless enthusiasm and commitment have helped many organisations to drive new innovations in cancer care.

It is with great sadness that we learn the death of Professor Hagenbeek. EORTC has lost a major contributor to its scientific agenda and a peer. Professor Hagenbeek has been leading many EORTC studies in the field of lymphoma research which have made a difference for patients, as well as acting as a true leader for the EORTC Lymphoma group. His vision and dedication to hematology, collaborating across the world, positioned him as a pioneer in clinical research already in the years 80s.

We will remember Professor Hagenbeek as a generous, passionate and talented scientist, doctor and clinical investigator, always going the extra mile, pushing relentlessly the boundaries of therapeutic progress for cancer patients.

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023